NDAORALCONCENTRATE
Approved
May 1976
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
3/8 — Basic
LOXITANE C (loxapine hydrochloride) by Teva is clinical pharmacology pharmacodynamics: pharmacologically, loxapine is an antipsychotic for which the exact mode of action has not been established. Approved for schizophrenia. First approved in 1976.
Drug data last refreshed 4d ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LOXITANE C is an oral antipsychotic concentrate containing loxapine hydrochloride, approved since 1976 for schizophrenia treatment. It works by modulating subcortical inhibitory areas, producing sedation and tranquilization effects within 20–30 minutes. The drug is rapidly absorbed, extensively metabolized, and primarily excreted within 24 hours.
LOE Approaching
As a legacy product approaching loss of exclusivity with moderate competitive pressure (30), the brand team is likely in transition or consolidation mode with limited growth headcount.
Mechanism of Action
CLINICAL PHARMACOLOGY Pharmacodynamics: Pharmacologically, loxapine is an antipsychotic for which the exact mode of action has not been established. However, changes in the level of excitability of subcortical inhibitory areas have been observed in several animal species in association with such…
Indications (1)
Worked on LOXITANE C at Teva? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.